JP2016510045A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510045A5 JP2016510045A5 JP2015560572A JP2015560572A JP2016510045A5 JP 2016510045 A5 JP2016510045 A5 JP 2016510045A5 JP 2015560572 A JP2015560572 A JP 2015560572A JP 2015560572 A JP2015560572 A JP 2015560572A JP 2016510045 A5 JP2016510045 A5 JP 2016510045A5
- Authority
- JP
- Japan
- Prior art keywords
- prevention
- treatment
- disorders
- disease
- neurodegenerative diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002265 prevention Effects 0.000 description 3
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000018254 acute transverse myelitis Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13001111.7 | 2013-03-05 | ||
| EP13001111 | 2013-03-05 | ||
| PCT/EP2014/000371 WO2014135245A1 (en) | 2013-03-05 | 2014-02-11 | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510045A JP2016510045A (ja) | 2016-04-04 |
| JP2016510045A5 true JP2016510045A5 (enExample) | 2017-03-16 |
| JP6409007B2 JP6409007B2 (ja) | 2018-10-17 |
Family
ID=47843002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560572A Expired - Fee Related JP6409007B2 (ja) | 2013-03-05 | 2014-02-11 | 抗癌剤としての９−（アリールまたはヘテロアリール）−２−（ピラゾリル、ピロリジニルまたはシクロペンチル）アミノプリン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9617266B2 (enExample) |
| EP (1) | EP2964648B1 (enExample) |
| JP (1) | JP6409007B2 (enExample) |
| CN (1) | CN105026397B (enExample) |
| AR (1) | AR094981A1 (enExample) |
| AU (1) | AU2014224976B2 (enExample) |
| CA (1) | CA2903901A1 (enExample) |
| ES (1) | ES2614872T3 (enExample) |
| IL (1) | IL240876B (enExample) |
| WO (1) | WO2014135245A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016005199B1 (pt) | 2013-08-23 | 2022-02-22 | Neupharma, Inc | Certos compostos químicos, composições, e métodos |
| WO2015038417A1 (en) * | 2013-09-10 | 2015-03-19 | Asana Biosciences, Llc | Compounds for regulating fak and/or src pathways |
| CA2961950A1 (en) * | 2014-09-28 | 2016-03-31 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
| EP3270694A4 (en) * | 2015-02-17 | 2018-09-05 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| CN104788441A (zh) * | 2015-04-02 | 2015-07-22 | 湖南华腾制药有限公司 | 一种多取代苯并恶唑衍生物的制备方法 |
| US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| JP6970126B2 (ja) * | 2016-06-02 | 2021-11-24 | セルジーン コーポレイション | 動物及びヒトの抗マラリア薬 |
| EP3464312A4 (en) * | 2016-06-02 | 2019-11-27 | Celgene Corporation | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS |
| SMT202100699T1 (it) | 2016-06-16 | 2022-01-10 | Denali Therapeutics Inc | Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi |
| HRP20241768T1 (hr) | 2016-08-10 | 2025-02-28 | Takeda Pharmaceutical Company Limited | Heterociklički spoj |
| WO2018035061A1 (en) | 2016-08-15 | 2018-02-22 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| CN114989205A (zh) | 2016-12-22 | 2022-09-02 | 卡里塞拉生物科学股份公司 | 用于抑制精氨酸酶活性的组合物和方法 |
| KR102383561B1 (ko) * | 2017-09-07 | 2022-04-06 | 한국화학연구원 | 테트라히드로이소퀴놀린기로 치환된 피리미딘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물 |
| KR102740831B1 (ko) | 2017-11-14 | 2024-12-11 | 칠드런'즈 메디컬 센터 코포레이션 | 신규 이미다조피리미딘 화합물 및 그의 용도 |
| EP3710007A4 (en) * | 2017-11-14 | 2021-12-15 | Children's Medical Center Corporation | USE OF IMIDAZOPYRIMIDINE TO MODULATE HUMAN IMMUNE RESPONSE |
| AU2018383709B2 (en) | 2017-12-12 | 2025-09-11 | Pionyr Immunotherapeutics, Inc. | Anti-TREM2 antibodies and related methods |
| WO2019136466A1 (en) | 2018-01-08 | 2019-07-11 | Yale University | Compounds and methods for treating or preventing anterior segment ocular disorders and/or retinal degenerations |
| BR112020015396A2 (pt) | 2018-01-29 | 2020-12-08 | Merck Patent Gmbh | Inididores de gcn2 e usos dos mesmos |
| JP7229257B2 (ja) * | 2018-01-29 | 2023-02-28 | メルク パテント ゲーエムベーハー | Ｇｃｎ２阻害剤およびその使用 |
| EP3802544A1 (en) | 2018-06-05 | 2021-04-14 | RAPT Therapeutics, Inc. | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses |
| CN111166750B (zh) * | 2018-11-09 | 2022-12-27 | 四川大学 | 一种4-氟-2-甲基吲哚类化合物的抗菌新用途 |
| TWI899080B (zh) * | 2019-05-27 | 2025-10-01 | 大陸商迪哲（江蘇）醫藥股份有限公司 | Ｄｎａ依賴性蛋白激酶抑制劑 |
| GB202008749D0 (en) | 2020-06-09 | 2020-07-22 | Ip2Ipo Innovations Ltd | Novel compounds |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| WO2025179188A1 (en) * | 2024-02-22 | 2025-08-28 | Juno Therapeutics, Inc. | Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| AU2004260738B2 (en) | 2003-07-16 | 2009-07-16 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| CN103251953A (zh) | 2004-07-19 | 2013-08-21 | 约翰·霍普金斯大学 | 供免疫抑制的flt3抑制剂 |
| JP5118972B2 (ja) | 2004-10-29 | 2013-01-16 | テイボテク・フアーマシユーチカルズ | Ｈｉｖ阻害性二環式ピリミジン誘導体 |
| ZA200706662B (en) * | 2005-01-13 | 2009-04-29 | Signal Pharmaceiticals Llc | Haloaryl substituted Aminopurines, compositions thereof, and methods of treatment therewith |
| US7723340B2 (en) * | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| WO2006075023A2 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| TWI398252B (zh) * | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| WO2011106168A1 (en) * | 2010-02-24 | 2011-09-01 | Dcam Pharma Inc | Purine compounds for treating autoimmune and demyelinating diseases |
| EA201300282A1 (ru) * | 2010-08-27 | 2013-08-30 | Мерк Патент Гмбх | Производные триазолопиразина |
-
2014
- 2014-02-11 EP EP14705029.8A patent/EP2964648B1/en not_active Not-in-force
- 2014-02-11 CA CA2903901A patent/CA2903901A1/en not_active Abandoned
- 2014-02-11 JP JP2015560572A patent/JP6409007B2/ja not_active Expired - Fee Related
- 2014-02-11 ES ES14705029.8T patent/ES2614872T3/es active Active
- 2014-02-11 CN CN201480012134.3A patent/CN105026397B/zh not_active Expired - Fee Related
- 2014-02-11 US US14/772,430 patent/US9617266B2/en not_active Expired - Fee Related
- 2014-02-11 WO PCT/EP2014/000371 patent/WO2014135245A1/en not_active Ceased
- 2014-02-11 AU AU2014224976A patent/AU2014224976B2/en not_active Ceased
- 2014-03-05 AR ARP140100696A patent/AR094981A1/es unknown
-
2015
- 2015-08-27 IL IL240876A patent/IL240876B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510045A5 (enExample) | ||
| PE20161220A1 (es) | Formulaciones de pridopidina de liberacion modificada | |
| WO2015191506A3 (en) | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles | |
| MX2018000688A (es) | Triciclicos sustituidos y metodo para usarlos. | |
| HK1206264A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2015120736A5 (enExample) | ||
| EA201071244A1 (ru) | Новые терапевтические подходы в лечении болезни альцгеймера и обусловленных ею расстройств посредством модуляции ангиогенеза | |
| JP2013519675A5 (enExample) | ||
| JP2019529514A5 (enExample) | ||
| WO2016087944A3 (en) | Method for treating alzheimer's disease | |
| JP2015500223A5 (enExample) | ||
| MX2015001917A (es) | Composiciones farmaceuticas de memantina. | |
| UA113750C2 (xx) | Склад (+)-2-$1-(3-етокси-4-метоксифеніл)-2-метансульфонілетил]-4-ацетиламіноізоіндолін-1,3-діону | |
| JP2017501140A5 (enExample) | ||
| JP2015520221A5 (enExample) | ||
| ZA202205344B (en) | Gene therapy for alzheimer's disease | |
| IL288266A (en) | Gene therapy for Alzheimer's disease | |
| JP2016537432A5 (enExample) | ||
| WO2015047982A3 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2016015798A9 (en) | Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population | |
| EP3801559A4 (en) | METHODS TO REDUCE LUNG EXACERBATIONS IN PATIENTS WITH RESPIRATORY DISEASES | |
| RU2020115710A (ru) | Терапевтические агенты для нейродегенеративных заболеваний | |
| EA202190359A1 (ru) | Способы лечения нейродегенеративных расстройств | |
| EP3085691A4 (en) | Method for preparing the anhydrous crystalline form of isoniazid-derived hydrazone, thus produced crystalline polymorph of the anhydrous form, use thereof for the treatment of alzheimer's disease, parkinsonism and other neurodegenerative disorders, and pharmaceutical composition | |
| WO2010135493A3 (en) | Alzheimer's disease imaging agents |